SCHEMBL384865

SCHEMBL384865

COc1cc2nc3ccccc3cc2c2cc3ccccc3nc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 9/20 0.55
TLR8 Q9NR97 1/20 0.51
NQO1 P15559 1/20 0.47
MAPT P10636 4/20 0.45
ALDH1A1 P00352 4/20 0.45
GLA P06280 2/20 0.45
HPGD P15428 2/20 0.45
ACHE P22303 1/20 0.45
RAB9A P51151 5/20 0.45
NPC1 O15118 4/20 0.45
KDM4E B2RXH2 4/20 0.45
POLB P06746 3/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
THRB P10828 2/20 0.45
BLM P54132 2/20 0.45
G6PD P11413 1/20 0.45
PKM P14618 1/20 0.45
MAPK1 P28482 1/20 0.45
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6972381 0.83 NQO2 (0.63) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL6259793 0.79 NQO2 (0.53) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL9406598 0.78 TLR8 (0.57) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL31124812 0.78 NQO2 (0.56) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL240664 0.77 NQO2 (0.57) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL17423273 0.77 NQO1 (0.52) NQO2TLR8NQO1MAPTALDH1A1
Hydrochloric Acid SCHEMBL15271481 0.76 NQO2 (0.56) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL8318316 0.75 TLR8 (0.54) NQO2TLR8NQO1MAPTALDH1A1
SCHEMBL14280967 0.75 TLR8 (0.50) NQO2TLR8NQO1MAPTALDH1A1
Hydrochloric Acid SCHEMBL32690198 0.75 NQO2 (0.54) NQO2TLR8NQO1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330456-B8 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-02-08 EP disclosed
EP-1330456-B9 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-01-25 EP disclosed
EP-1330456-B1 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2011-06-15 EP disclosed
US-7115619-B2 N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-10-03 US disclosed
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-04-01 US disclosed
EP-1330456-A2 N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2003-07-30 EP disclosed
WO-2002030932-A2 N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents TERT, MKI67, NQO2 NQO2 3/4885TLR8 2021/4885NQO1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.